The dramatically lower GPR‐120 concentrations observed in nephropathy align with the concept that persistent hyperglycemia, oxidative stress, and inflammatory mediators collectively impair the beneficial effects of GPR‐120 in modulating lipid metabolism and inflammatory signaling [19,20]. Here, FFAR4 is linked to kidney disorder.